Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Veracyte, Inc. (VCYT)

NGM · Diagnostics & Research

$55.65+0.04 (+0.07%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$4.44B
P/E (TTM)
51.53
EPS
$1.08
Div Yield
52W Range
$22.92–$60.91
Beta
1.93

Company overview

Next earnings: 2026-07-30(2d)

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Peers in Diagnostics & Research

All in industry →

Recent press releases

April 2026

3 months agoARSHealthcare

Please provide the actual SEC filing content for the headline to be generated. The current input is a request for information, not a summary of a filing

VCYTVERACYTE, INC.

I apologize, but the content for the SEC filing for Veracyte, Inc. (VCYT) was not included in the request. The input provided only contained the document metadata but no actual text, PDF, or narrative content. As an expert financial analyst, I need the document's content to provide the comprehensiv

Read summaryView on SEC EDGAR
3 months agoDEF 14AHealthcare

VCYT seeks shareholder vote approving 3.5 million shares for equity plan

VCYTVERACYTE, INC.

# 📜 What This Document Is ℹ️ This is a Definitive Proxy Statement (a DEF 14A), which is a highly formal document filed with the SEC that tells shareholders exactly what decisions they will be voting on at the company's Annual Meeting. Think of it as a "playbook" for the annual meeting, outlining th

Read summaryView on SEC EDGAR

SEC filings

All filings →
2 recent filings shown in the timeline above. View all SEC filings →

Veracyte, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
13,128,801 sh+0.6%
8,504,011 sh0.0%
4,360,913 sh+3.8%
2,036,386 sh-39.6%
631,710 sh● NEW
980,391 sh+102.1%
1,561,449 sh-38.7%

People at Veracyte, Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
$3.6M
NI $7.0M
06/25
$3.6M
NI -$980.0K
09/25
$131.9M
NI $19.1M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $0.24
Prior: $-0.01
Revenue sparkline